LncRNA RP11-502Ⅰ4.3在增殖期糖尿病视网膜病变的差异表达研究-现代医学

LncRNA RP11-502Ⅰ4.3在增殖期糖尿病视网膜病变的差异表达研究

单位：遵义医科大学第三附属医院/遵义市第一人民医院眼科, 贵州遵义 563000

关键词：糖尿病视网膜病变长链非编码RNA RP11-502Ⅰ4.3 新生血管实时荧光定量PCR

分类号：R587.2;R774.1

出版年·卷·期（页码）：2026·54·第七期（1116-1124）

摘要：

目的：探讨长链非编码RNA(lncRNA) RP11-502Ⅰ4.3在增殖期糖尿病视网膜病变(PDR)中的表达及意义。方法：采用实时荧光定量PCR(qRT-PCR)技术检测PDR患者(n=11)与特发性黄斑裂孔(IMH)患者(n=6)玻璃体液中lncRNA RP11-502Ⅰ4.3的表达水平；同时检测链脲佐菌素(STZ)诱导的糖尿病大鼠与正常大鼠视网膜组织，以及高糖(30 mmol·L^-1)与正常糖浓度(5.5 mmol·L^-1)培养的人视网膜微血管内皮细胞(hRMEC)中lncRNA RP11-502Ⅰ4.3的表达。采用CCK-8、Transwell及管形成实验分别评估高糖对hRMEC增殖、迁移及成管能力的影响。结果： LncRNA RP11-502Ⅰ4.3在PDR患者玻璃体液、糖尿病大鼠视网膜组织及高糖诱导的hRMEC中表达均显著下调(均P<0.05)。功能实验显示，高糖可显著增强hRMEC的增殖、迁移及管形成能力。结论： LncRNA RP11-502Ⅰ4.3在PDR中低表达，其表达下调可能参与PDR的发病过程。

Objective: To investigate the expression and significance of long non-coding RNA RP11-502Ⅰ4.3 in proliferative diabetic retinopathy(PDR). Methods: Quantitative real-time PCR(qRT-PCR) was used to detect the expression of lncRNA RP11-502Ⅰ4.3 in the vitreous humor of patients with PDR(n=11) and idiopathic macular hole(IMH,n=6). The expression of lncRNA RP11-502Ⅰ4.3 was also examined in the retinal tissues of streptozotocin(STZ)-induced diabetic rats versus normal rats, as well as in human retinal microvascular endothelial cell(hRMEC) cultured under high glucose(30 mmol·L^-1) versus normal glucose(5.5 mmol·L^-1) conditions. The effects of high glucose on hRMEC proliferation, migration, and tube formation were assessed using CCK-8, Transwell, and tube formation assay, respectively. Results: LncRNA RP11-502Ⅰ4.3 expression was significantly downregulated in the vitreous humor of PDR patients, the retinal tissue of diabetic rats, and high glucose-induced hRMEC(all P<0.05). Functional assays showed that high glucose significantly enhanced the proliferation, migration, and tube formation ability of hRMEC. Conclusion: LncRNA RP11-502Ⅰ4.3 is downregulated in PDR, suggesting that its decreased expression may contribute to the pathogenesis of PDR.

参考文献：

[1] SUN H,SAEEDI P,KARURANGA S,et al.IDF Diabetes Atlas:global,regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J].Diabetes Res Clin Pract,2022,183:109119.
[2] WANG Z,ZHANG N,LIN P,et al.Recent advances in the treatment and delivery system of diabetic retinopathy[J].Front Endocrinol,2024,15:1347864.
[3] 姚娜.2型糖尿病患者血清ADAM10、FGF23水平与糖尿病视网膜病变的相关性研究[J].现代医学,2025,53(9):1431-1437.
[4] GANDHI P,WANG Y,LI G,et al.The role of long noncoding RNAs in ocular angiogenesis and vascular oculopathy[J].Cell Biosci,2024,14(1):39.
[5] SHARMA A,SINGH N K.Long non-coding RNAs and proliferative retinal diseases[J].Pharmaceutics,2023,15(5):1454.
[6] YAN B,TAO Z F,LI X M,et al.Aberrant expression of long noncoding RNAs in early diabetic retinopathy[J].Invest Ophthalmol Vis Sci,2014,55(2):941.
[7] THOMAS A A,FENG B,CHAKRABARTI S.ANRIL:a regulator of VEGF in diabetic retinopathy[J].Invest Ophthalmol Vis Sci,2017,58(1):470.
[8] YU C,YANG K,MENG X,et al.Downregulation of long noncoding RNA MIAT in the retina of diabetic rats with tail-vein injection of human umbilical-cord mesenchymal stem cells[J].Int J Med Sci,2020,17(5):591-598.
[9] LUO R,JIN H,LI L,et al.Long noncoding RNA MEG3 inhibits apoptosis of retinal pigment epithelium cells induced by high glucose via the miR-93/Nrf2 axis[J].Am J Pathol,2020,190(9):1813-1822.
[10] THOMAS A A,BISWAS S,FENG B,et al.LncRNA H19 prevents endothelial-mesenchymal transition in diabetic retinopathy[J].Diabetologia,2019,62(3):517-530.
[11] TORAIH E A,ABDELGHANY A A,ABD EL FADEAL N M,et al.Deciphering the role of circulating lncRNAs:RNCR2,NEAT2,CDKN2B-AS1,and PVT1 and the possible prediction of anti-VEGF treatment outcomes in diabetic retinopathy patients[J].Graefe's Arch Clin Exp Ophthalmol,2019,257(9):1897-1913.
[12] YIN L,SUN Z,REN Q,et al.Long non-coding RNA BANCR is overexpressed in patients with diabetic retinopathy and promotes apoptosis of retinal pigment epithelial cells[J].Med Sci Monit,2019,25:2845-2851.
[13] SHAO K,XI L,CANG Z,et al.Knockdown of NEAT1 exerts suppressive effects on diabetic retinopathy progression via inactivating TGF-β1 and VEGF signaling pathways[J].J Cell Physiol,2020,235(12):9361-9369.
[14] 闫爱民,彭凯,陈凤华.玻璃体切除联合硅油填充术后视力下降的发生率及其影响因素[J].现代医学,2022,50(5):604-607.
[15] CUBILLOS S,KAZLAUSKAS A.Manifestation of pathology in animal models of diabetic retinopathy is delayed from the onset of diabetes[J].Int J Mol Sci,2024,25(3):1610.
[16] CATALDI S,TRAMONTANO M,COSTA V,et al.Diabetic retinopathy:are lncRNAs new molecular players and targets?[J].Antioxidants,2022,11(10):2021.
[17] TAYLOR B E,LEE C A,ZAPADKA T E,et al.IL-17A enhances retinal neovascularization[J].Int J Mol Sci,2023,24(2):1747.
[18] SMALLEY E.First AAV gene therapy poised for landmark approval[J].Nat Biotechnol,2017,35(11):998-999.
[19] MANDAVA N,TIRADO-GONZALEZ V,GEIGER M D,et al.Complement activation in the vitreous of patients with proliferative diabetic retinopathy[J].Invest Ophthalmol Vis Sci,2020,61(11):39.
[20] TOMITA Y,CAGNONE G,FU Z,et al.Vitreous metabolomics profiling of proliferative diabetic retinopathy[J].Diabetologia,2021,64(1):70-82.
[21] WU F,PHONE A,LAMY R,et al.Correlation of aqueous,vitreous,and plasma cytokine levels in patients with proliferative diabetic retinopathy[J].Invest Ophthalmol Vis Sci,2020,61(2):26.
[22] ZANDI S,TAPPEINER C,PFISTER I B,et al.Vitreal cytokine profile differences between eyes with epiretinal membranes or macular holes[J].Invest Ophthalmol Vis Sci,2016,57(14):6320.
[23] GARDNER T W,DAVILA J R.The neurovascular unit and the pathophysiologic basis of diabetic retinopathy[J].Graefe's Arch Clin Exp Ophthalmol,2017,255(1):1-6.
[24] 李亚蓉,毛红,李娜,等.血管内皮生长因子、血管细胞间黏附分子与增殖型糖尿病视网膜病变的相关性及联合诊断价值研究[J].现代医学,2021,49(4):395-399.
[25] PAPETTI M,HERMAN I M.Mechanisms of normal and tumor-derived angiogenesis[J].Am J Physiol Cell Physiol,2002,282(5):C947-C970.
[26] RIBATTI D,CRIVELLATO E.“Sprouting angiogenesis”,a reappraisal[J].Dev Biol,2012,372(2):157-165.
[27] HOYING J B,UTZINGER U,WEISS J A.Formation of microvascular networks:role of stromal interactions directing angiogenic growth[J].Microcirculation,2014,21(4):278-289.
[28] EELEN G,DE ZEEUW P,TREPS L,et al.Endothelial cell metabolism[J].Physiol Rev,2018,98(1):3-58.
[29] MIYAMOTO K,HIROSHIBA N,TSUJIKAWA A,et al.In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats [J].Invest Ophthalmol Vis Sci,1998,39(11):2190-2194.
[30] YUUKI T,KANDA T,KIMURA Y,et al.Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy[J].J Diabetes Complicat,2001,15(5):257-259.
[31] ROY S,KERN T S,SONG B,et al.Mechanistic insights into pathological changes in the diabetic retina implications for targeting diabetic retinopathy[J].Am J Pathol,2017,187(1):9-19.
[32] RüBSAM A,PARIKH S,FORT P.Role of inflammation in diabetic retinopathy[J].Int J Mol Sci,2018,19(4):942.
[33] WANG J,XU X,ELLIOTT M H,et al.Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage[J].Diabetes,2010,59(9):2297-2305.
[34] ANTONETTI D A,KLEIN R,GARDNER T W.Diabetic retinopathy[J].N Engl J Med,2012,366(13):1227-1239.
[35] MASUDA T,SHIMAZAWA M,HARA H.Retinal diseases associated with oxidative stress and the effects of a free radical scavenger(edaravone)[J].Oxid Med Cell Longev,2017,2017:9208489.
[36] CARMELIET P.Mechanisms of angiogenesis and arteriogenesis[J].Nat Med,2000,6(4):389-395.
[37] ROSENBERG K I,TEWARI A.Visualizing the internal limiting membrane:what is effective and what is safe?[J].Int Ophthalmol Clin,2014,54(2):39-49.
[38] YANG J,LIU Z.Mechanistic pathogenesis of endothelial dysfunction in diabetic nephropathy and retinopathy[J].Front Endocrinol,2022,13:816400.
[39] XU M,FAN R,FAN X,et al.Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis[J].Drug Des Dev Ther,2022,16:3241-3262.
[40] MUKWAYA A,JENSEN L,LAGALI N.Relapse of pathological angiogenesis:functional role of the basement membrane and potential treatment strategies[J].Exp Mol Med,2021,53(2):189-201.
[41] HUANG H.Pericyte-endothelial interactions in the retinal microvasculature[J].Int J Mol Sci,2020,21(19):7413.
[42] WANG M,LI Q,JIN M,et al.Noncoding RNAs are promising therapeutic targets for diabetic retinopathy:an updated review(2017—2022)[J].Biomolecules,2022,12(12):1774.
[43] REDDY S K,DEVI V,SEETHARAMAN A T M,et al.Cell and molecular targeted therapies for diabetic retinopathy[J].Front Endocrinol,2024,15:1416668.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录